NASDAQ:MLNT - Melinta Therapeutics News Headlines

Sign in or create an account to add this stock to your watchlist.
$4.06 -0.22 (-5.14 %)
(As of 03/22/2019 04:00 PM ET)
Previous Close$4.06
Today's Range$4.05 - $4.27
52-Week Range$3.20 - $46.50
Volume169,176 shs
Average Volume648,180 shs
Market Capitalization$45.59 million
P/E Ratio-0.23
Dividend YieldN/A
Beta2.28

Headlines

Melinta Therapeutics (NASDAQ MLNT) News Headlines

Source:
DateHeadline
$17.50 Million in Sales Expected for Melinta Therapeutics Inc (MLNT) This Quarter$17.50 Million in Sales Expected for Melinta Therapeutics Inc (MLNT) This Quarter
www.americanbankingnews.com - March 22 at 3:16 AM
 Analysts Anticipate Melinta Therapeutics Inc (MLNT) Will Announce Earnings of -$3.03 Per Share Analysts Anticipate Melinta Therapeutics Inc (MLNT) Will Announce Earnings of -$3.03 Per Share
www.americanbankingnews.com - March 20 at 12:47 PM
Melinta Therapeutics Inc (MLNT) Receives Average Recommendation of "Buy" from BrokeragesMelinta Therapeutics Inc (MLNT) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - March 20 at 2:19 AM
Gabelli Comments on Melinta Therapeutics Incs FY2023 Earnings (MLNT)Gabelli Comments on Melinta Therapeutics Inc's FY2023 Earnings (MLNT)
www.americanbankingnews.com - March 18 at 2:35 AM
Melinta Therapeutics Inc.Melinta Therapeutics Inc.
www.barrons.com - March 14 at 7:07 PM
Head to Head Analysis: Melinta Therapeutics (MLNT) and MacroGenics (MGNX)Head to Head Analysis: Melinta Therapeutics (MLNT) and MacroGenics (MGNX)
www.americanbankingnews.com - March 14 at 2:06 AM
Melinta Therapeutics Reports Fourth Quarter and Full-Year 2018 Financial ResultsMelinta Therapeutics Reports Fourth Quarter and Full-Year 2018 Financial Results
www.globenewswire.com - March 13 at 6:56 PM
Melinta Q4 product sales $14.6M; shares up 14% after hoursMelinta Q4 product sales $14.6M; shares up 14% after hours
seekingalpha.com - March 13 at 6:56 PM
Melinta Therapeutics Reports Fourth Quarter and Full-Year 2018 Financial ResultsMelinta Therapeutics Reports Fourth Quarter and Full-Year 2018 Financial Results
finance.yahoo.com - March 13 at 6:55 PM
Melinta Therapeutics, Inc. (MLNT) Reports Q4 Loss, Tops Revenue EstimatesMelinta Therapeutics, Inc. (MLNT) Reports Q4 Loss, Tops Revenue Estimates
finance.yahoo.com - March 13 at 6:55 PM
Melinta Therapeutics (MLNT) Scheduled to Post Quarterly Earnings on WednesdayMelinta Therapeutics (MLNT) Scheduled to Post Quarterly Earnings on Wednesday
www.americanbankingnews.com - March 6 at 8:40 AM
Melinta Therapeutics to Report Fourth Quarter and Year-End 2018 Financial Results on March 13, 2019Melinta Therapeutics to Report Fourth Quarter and Year-End 2018 Financial Results on March 13, 2019
finance.yahoo.com - March 5 at 8:58 AM
Melinta Therapeutics Inc (MLNT) Short Interest UpdateMelinta Therapeutics Inc (MLNT) Short Interest Update
www.americanbankingnews.com - March 3 at 5:35 AM
 Analysts Anticipate Melinta Therapeutics Inc (MLNT) Will Post Quarterly Sales of $17.77 Million Analysts Anticipate Melinta Therapeutics Inc (MLNT) Will Post Quarterly Sales of $17.77 Million
www.americanbankingnews.com - February 27 at 2:44 AM
Melinta closes $75M convertible loan funding; shares down 14% premarketMelinta closes $75M convertible loan funding; shares down 14% premarket
seekingalpha.com - February 25 at 6:51 PM
Melinta Therapeutics Announces Closing of Initial $75 Million Vatera Convertible Loan FundingMelinta Therapeutics Announces Closing of Initial $75 Million Vatera Convertible Loan Funding
finance.yahoo.com - February 25 at 9:03 AM
Melinta Therapeutics Announces One-for-Five Reverse Stock Split - NasdaqMelinta Therapeutics Announces One-for-Five Reverse Stock Split - Nasdaq
www.nasdaq.com - February 22 at 8:42 AM
Melinta Therapeutics (MLNT) Board Approves 1-for-5 Reverse Stock Split - StreetInsider.comMelinta Therapeutics (MLNT) Board Approves 1-for-5 Reverse Stock Split - StreetInsider.com
www.streetinsider.com - February 21 at 6:46 PM
Melinta Therapeutics Announces One-for-Five Reverse Stock Split - GlobeNewswireMelinta Therapeutics Announces One-for-Five Reverse Stock Split - GlobeNewswire
globenewswire.com - February 21 at 6:46 PM
Melinta Therapeutics Announces One-for-Five Reverse Stock SplitMelinta Therapeutics Announces One-for-Five Reverse Stock Split
finance.yahoo.com - February 21 at 6:46 PM
Melinta Therapeutics Provides Corporate UpdatesMelinta Therapeutics Provides Corporate Updates
finance.yahoo.com - February 4 at 9:24 AM
Melinta Therapeutics Announces Commitment for New Credit Facility of Up to $135 MillionMelinta Therapeutics Announces Commitment for New Credit Facility of Up to $135 Million
finance.yahoo.com - December 19 at 8:39 AM
John H. Johnson Agrees to Become Permanent Chief Executive Officer of Melinta TherapeuticsJohn H. Johnson Agrees to Become Permanent Chief Executive Officer of Melinta Therapeutics
finance.yahoo.com - December 19 at 8:39 AM
Dova Pharmaceuticals Announces Management ChangesDova Pharmaceuticals Announces Management Changes
finance.yahoo.com - December 17 at 8:35 AM
INVESTIGATION NOTICE: Kaskela Law LLC Announces Investigation of Melinta Therapeutics, Inc. on Behalf of Stockholders – MLNTINVESTIGATION NOTICE: Kaskela Law LLC Announces Investigation of Melinta Therapeutics, Inc. on Behalf of Stockholders – MLNT
globenewswire.com - December 1 at 8:43 AM
INVESTIGATION NOTICE:  Kaskela Law LLC Announces Investigation of Melinta Therapeutics, Inc. on Behalf of Stockholders – MLNTINVESTIGATION NOTICE:  Kaskela Law LLC Announces Investigation of Melinta Therapeutics, Inc. on Behalf of Stockholders – MLNT
finance.yahoo.com - November 30 at 5:35 PM
Melinta Therapeutics (MLNT) Announces European Commission Marketing Authorization for VabomereMelinta Therapeutics (MLNT) Announces European Commission Marketing Authorization for Vabomere
www.streetinsider.com - November 27 at 5:06 PM
Melintas Vabomere OKd in EuropeMelinta's Vabomere OK'd in Europe
seekingalpha.com - November 27 at 8:54 AM
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by the Board of Directors of Melinta Therapeutics, Inc.  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by the Board of Directors of Melinta Therapeutics, Inc.  
finance.yahoo.com - November 27 at 8:54 AM
Melinta Therapeutics Granted European Commission Marketing Authorization for Vabomere® (meropenem and vaborbactam)Melinta Therapeutics Granted European Commission Marketing Authorization for Vabomere® (meropenem and vaborbactam)
finance.yahoo.com - November 27 at 8:54 AM
STOCKHOLDER ALERT: Kaskela Law LLC Announces Investigation of Melinta Therapeutics, Inc. - MLNTSTOCKHOLDER ALERT: Kaskela Law LLC Announces Investigation of Melinta Therapeutics, Inc. - MLNT
finance.yahoo.com - November 25 at 8:30 AM
New Research: Key Drivers of Growth for Fresh Del Monte Produce, Liquidity Services, B.O.S. Better Online Solutions, ePlus inc, Pluralsight, and Melinta Therapeutics — Factors of Influence, Major Initiatives and Sustained ProductionNew Research: Key Drivers of Growth for Fresh Del Monte Produce, Liquidity Services, B.O.S. Better Online Solutions, ePlus inc, Pluralsight, and Melinta Therapeutics — Factors of Influence, Major Initiatives and Sustained Production
finance.yahoo.com - November 16 at 8:27 AM
Nektar (NKTR) Catches Eye: Stock Jumps 8.7%Nektar (NKTR) Catches Eye: Stock Jumps 8.7%
www.zacks.com - November 13 at 8:26 AM
MELINTA THERAPEUTICS, INC.MELINTA THERAPEUTICS, INC.
www.streetinsider.com - November 8 at 8:37 AM
Melinta Therapeutics, Inc. (MLNT) Management on Q3 2018 Results - Earnings Call TranscriptMelinta Therapeutics, Inc. (MLNT) Management on Q3 2018 Results - Earnings Call Transcript
seekingalpha.com - November 8 at 8:37 AM
Melinta Therapeutics, Inc. (MLNT) Reports Q3 Loss, Tops Revenue EstimatesMelinta Therapeutics, Inc. (MLNT) Reports Q3 Loss, Tops Revenue Estimates
finance.yahoo.com - November 7 at 5:32 PM
Melinta Therapeutics, Inc.: 3Q Earnings SnapshotMelinta Therapeutics, Inc.: 3Q Earnings Snapshot
finance.yahoo.com - November 7 at 5:32 PM
Melinta Therapeutics Reports Third Quarter 2018 Financial ResultsMelinta Therapeutics Reports Third Quarter 2018 Financial Results
finance.yahoo.com - November 7 at 8:36 AM
Analysts Estimate Melinta Therapeutics, Inc. (MLNT) to Report a Decline in Earnings: What to Look Out forAnalysts Estimate Melinta Therapeutics, Inc. (MLNT) to Report a Decline in Earnings: What to Look Out for
www.zacks.com - November 1 at 8:22 AM
UPDATE - Melinta Therapeutics Announces Appointment of Bruce L. Downey to Board of DirectorsUPDATE - Melinta Therapeutics Announces Appointment of Bruce L. Downey to Board of Directors
www.nasdaq.com - November 1 at 8:22 AM
Melinta Therapeutics Announces Appointment of Bruce L. Downey to Board of DirectorsMelinta Therapeutics Announces Appointment of Bruce L. Downey to Board of Directors
finance.yahoo.com - October 31 at 5:14 PM
The Daily Biotech Pulse: Pfizer And Allergan Earnings, CFO Departures At Acadia And AssertioThe Daily Biotech Pulse: Pfizer And Allergan Earnings, CFO Departures At Acadia And Assertio
www.benzinga.com - October 30 at 8:35 AM
Melinta Therapeutics Loses Again Despite Positive Phase 3 ResultsMelinta Therapeutics Loses Again Despite Positive Phase 3 Results
247wallst.com - October 29 at 4:51 PM
Melinta up 11% premarket on positive delafloxacin dataMelinta up 11% premarket on positive delafloxacin data
seekingalpha.com - October 29 at 9:14 AM
Melinta Therapeutics Announces Positive Top-Line Results in Phase III Trial of Baxdela® (delafloxacin) for Treatment of CABPMelinta Therapeutics Announces Positive Top-Line Results in Phase III Trial of Baxdela® (delafloxacin) for Treatment of CABP
finance.yahoo.com - October 29 at 9:14 AM
Melinta Therapeutics, Inc. (MLNT) Q3 Earnings Preview: What to Know Ahead of the ReleaseMelinta Therapeutics, Inc. (MLNT) Q3 Earnings Preview: What to Know Ahead of the Release
www.zacks.com - October 26 at 8:42 AM
Melinta Therapeutics to Report Third Quarter 2018 Financial Results on November 7, 2018Melinta Therapeutics to Report Third Quarter 2018 Financial Results on November 7, 2018
finance.yahoo.com - October 26 at 8:42 AM
Melinta Therapeutics Announces Appointment of John H. Johnson as Interim Chief Executive OfficerMelinta Therapeutics Announces Appointment of John H. Johnson as Interim Chief Executive Officer
finance.yahoo.com - October 22 at 8:32 AM
Melinta Therapeutics Publishes Findings from Orbactiv® (oritavancin) Real-World Registry Demonstrating Efficacy and Safety Consistent with Phase 3 SOLO ProgramMelinta Therapeutics Publishes Findings from Orbactiv® (oritavancin) Real-World Registry Demonstrating Efficacy and Safety Consistent with Phase 3 SOLO Program
finance.yahoo.com - October 5 at 8:34 AM
Melinta Therapeutics publishes complete results from Phase III TANGO 2 study of VabomereMelinta Therapeutics publishes complete results from Phase III TANGO 2 study of Vabomere
seekingalpha.com - October 2 at 4:45 PM
This page was last updated on 3/23/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel